Use of Tocilizumab in Management of Post-Operative Myelomonocytic Leukemoid Reaction

Megan Melody, Emily Butts, David Menke, Kevin Landolfo, Keith Oken, Taimur Sher, Sharad Khurana

Research output: Contribution to journalArticlepeer-review


Interleukin 6 receptor (IL6R) inhibitor, tocilizumab, has been effectively used in the treatment of cytokine release syndrome in patients receiving chimeric antigen receptor T-cell therapy. Here we present a patient with chronic myelomonocytic leukemia (CMML) who developed a steroid refractory, post-operative myelomonocytic leukemoid reaction (PO-MMLR), effectively treated with tocilizumab. Although, further studies are needed to validate the effectiveness of tocilizumab in management of PO-MMLR, this case serves to provide a new management approach in treatment of this rare but lethal syndrome with no standardized treatment options.

Original languageEnglish (US)
Article number100228
JournalLeukemia Research Reports
StatePublished - Jan 2020


  • Chronic myelomonocytic leukemia
  • Leukemoid reaction
  • Systemic inflammatory response
  • Tocilizumab

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Use of Tocilizumab in Management of Post-Operative Myelomonocytic Leukemoid Reaction'. Together they form a unique fingerprint.

Cite this